Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Against the background of an increasingly aging global population, the incidence of thrombotic and hemostatic diseases, including cardiovascular diseases, remains high.

JP Morgan, BTIG, and Jefferies announced separately Monday that they have initiated coverage of molecular diagnostics firm BillionToOne.

Circular Genomics announced Monday that it raised $15 million in a Series A financing round led by Mountain Group Partners.

In honour of World AIDS Day 2025, AIDS Healthcare Foundation (AHF) UK will host two community events to emphasize that the work to end HIV/AIDS is not over.

Cardiologists and primary-care physicians at a Midwest hospital system are using a polygenic risk score (PRS) to identify patients at risk for heart attacks who could benefit from more aggressive treatment.

Myriad Genetics, Clairity, and MagView said on 25 Nov that they have integrated their products to improve personalized breast cancer risk assessment.

Bengaluru-based deep-tech startup Morphle Labs has raised USD 5 million in a Series A round led by Inflexor Ventures to expand its physical AI-based automation systems for cancer diagnostics.

India has taken a significant step forward in the field of immunology with the launch of its first dedicated complement testing laboratory, designed to improve the diagnosis of complex autoimmune and inflammatory diseases.

The US Food and Drug Administration on Tuesday released a proposal to reclassify companion diagnostic assays from Class III medical devices to Class II devices.

The College of American Pathologists (CAP) on Monday released guidelines for accurate diagnosis of amyloidosis, emphasizing the importance of identifying subtypes of the rare disease caused by hereditary mutations that can be targeted for treatment.

Ovation.io, a leading human omics and clinical data company, and PrecisionLife, a precision medicine company transforming how complex chronic diseases are understood and managed, today announced a collaboration to develop drug-response biomarkers for glucagon-like peptide-1 receptor agonist (GLP-1) therapies. The resulting insights will potentially underpin a payor-facing test to inform reimbursement policy for these widely prescribed drugs based on a patient's potential to tolerate and respond to a drug in specific indications.